The gap between the 24.06x trailing P/E and 16.15x forward P/E, mirrored by EV/EBITDA stepping from 22.26x to 13.21x, embeds an earnings recovery that is plausible only if quarterly revenue normalizes toward the 2027Q1 level rather than the 2027Q2 print of $5.8M. Against peers, the 13.88x P/S stands well above MPWR's 91.55x P/E but on a fundamentally different sales base, while the 4.50 PEG versus MPWR's 3.10 suggests NVEC is priced for growth it has not demonstrated over the last ten quarters. The 5.3% yield, the highest in the peer set, may be doing more valuation work than the growth multiples, which warrants scrutiny given that the payout has exceeded period free cash flow.

The most reliable read of true earning power appears to be the operating margin rather than net margin, since net income topped operating income in four of ten quarters — 2026Q4's 64.4% net margin against 61.9% operating margin implies a non-operating contribution that is not repeatable by conviction. Operating margin has held a 55.0%-65.8% band while gross margin eroded roughly 780 basis points, meaning the company absorbed gross pressure through a cost base consuming only about 23% of revenue rather than through pricing power. The 99.3% FCF margin in 2027Q2 should be discounted as a working-capital release coinciding with a 47% sequential revenue decline, not as a margin trend.

ROE and ROA track within 10-40 basis points of each other throughout, confirming that with a D/E of 0.02 the entire return profile is margin and asset-utilization driven, leaving no leverage contribution to smooth the swing between 4.8% and 10.8% ROE. ROIC's peak of 9.5% followed by a drop to 4.3% in 2027Q2 mirrors the revenue reversal, implying the return inflection was demand-timing rather than a structural improvement in the cost of capital employed. Compared with MPWR's 22.2% ROIC, NVEC appears to be a high-margin, low-velocity business whose capital is not being compounded at rates that would justify reinvestment-led valuation, and investors should monitor whether retained cash is redeployed or simply distributed.

The CCC has compressed from 897 days in 2025Q3 to 550 days, but the improvement reads as inventory drawdown alongside falling revenue rather than as a structural efficiency gain, since DIO still accounts for roughly 89% of the cycle. DPO's 11-19 day range across the entire period indicates essentially no supplier financing, so the company funds its own cycle outright — a conservative posture that also signals limited bargaining power over payment terms. The DSO jump from 45 to 79 days in 2027Q2, arriving in the same quarter revenue fell 47%, suggests collections may be lagging and warrants monitoring against the flat receivables-driven FCF reading.

The current ratio has ranged from 16.10 to 40.30 over ten quarters against total liabilities of roughly $1.9M, which on reported figures would withstand any plausible stress scenario without recourse to external financing. The 5.7x spread between current and quick ratios implies inventory is a meaningful slice of the liquidity cushion, and with DIO at 490 days that inventory may be slow to monetize in a downside. The more relevant pressure is not solvency but sustainability: at approximately $4.8M in quarterly dividends against period cumulative FCF of about $38.5M, the buffer appears to be funding the payout, consistent with equity declining from $64.9M to $58.0M.